Cargando…

Editorial: Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine

Detalles Bibliográficos
Autor principal:	Melosky, Barbara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733540/ https://www.ncbi.nlm.nih.gov/pubmed/29322030 http://dx.doi.org/10.3389/fonc.2017.00311

Ejemplares similares

Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer
por: Melosky, Barbara
Publicado: (2014)

Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials
por: Melosky, Barbara
Publicado: (2014)

Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer
por: Melosky, Barbara
Publicado: (2017)

Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR–TKIs
por: Melosky, Barbara, et al.
Publicado: (2014)

Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine
por: Soldera, Sara Victoria, et al.
Publicado: (2017)

The Treatment of Metastatic Non-Small Cell Lung Cancer in a New Era of Personalized Medicine
por: Hirsh, Vera
Publicado: (2015)

Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine
por: Graham, Donna M., et al.
Publicado: (2014)

Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib
por: Melosky, B., et al.
Publicado: (2008)

Editorial: Personalised multimodal prehabilitation in cancer
por: West, MA., et al.
Publicado: (2022)

Pharmacogenomics in the era of personalised medicine
por: White, Cassandra, et al.
Publicado: (2022)

Low Grade Neuroendocrine Tumors of the Lung
por: Melosky, Barbara
Publicado: (2017)

Antiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine
por: Tabchi, Samer, et al.
Publicado: (2017)

Editorial: Update on the Biology, Management, and Treatment of Small Cell Lung Cancer
por: Puri, Sonam, et al.
Publicado: (2020)

Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC
por: Bansal, Pranshu, et al.
Publicado: (2016)

Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
por: Blais, Normand, et al.
Publicado: (2014)

Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC
por: Zer, Alona, et al.
Publicado: (2014)

Erratum: Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
Publicado: (2014)

Recent Advances in Immunotherapy in Metastatic NSCLC
por: Bansal, Pranshu, et al.
Publicado: (2016)

Editorial: Imaging in non-small cell lung cancer
por: Liu, Yiyan
Publicado: (2023)

New era of personalised epilepsy management
por: Chen, Zhibin, et al.
Publicado: (2020)

SRC and MEK Co-inhibition Synergistically Enhances the Anti-tumor Effect in Both Non-small-cell Lung Cancer (NSCLC) and Erlotinib-Resistant NSCLC
por: Yuan, Man, et al.
Publicado: (2019)

Editorial: Immunotherapy for NSCLC with oncogenic driver variants
por: Du, Yijia, et al.
Publicado: (2022)

Editorial: Prognostic factors in non-small cell lung cancer
por: Rahouma, Mohamed, et al.
Publicado: (2023)

Role of Radiotherapy in Metastatic Non-Small Cell Lung Cancer
por: Faria, Sergio L.
Publicado: (2014)

Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
por: Iafolla, Marco A. J., et al.
Publicado: (2017)

The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer
por: Melosky, Barbara, et al.
Publicado: (2021)

Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future Prospects
por: Ryu, Rachel, et al.
Publicado: (2018)

Editorial: Overcoming drug relapse and therapy resistance in NSCLC
por: Parakh, Sagun, et al.
Publicado: (2023)

Editorial: Factors that impact the survival of non-small cell lung cancer
por: Hegi-Johnson, Fiona, et al.
Publicado: (2023)

Editorial: An era of personalized medicine in breast cancer: integrating artificial intelligence into practice
por: Masood, Nosheen, et al.
Publicado: (2023)

Blood Tumor Mutational Burden as a Predictive Biomarker in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
por: Ma, Yuhui, et al.
Publicado: (2021)

Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients
por: Patel, Yuti P., et al.
Publicado: (2021)

Hypoxia-activated prodrugs: paths forward in the era of personalised medicine
por: Hunter, Francis W, et al.
Publicado: (2016)

Editorial: Emerging Biomarkers for NSCLC: Recent Advances in Diagnosis and Therapy
por: Malapelle, Umberto, et al.
Publicado: (2021)

Editorial: Treatment for Non-Small Cell Lung Cancer in Distinct Patient Populations
por: Uchino, Junji, et al.
Publicado: (2022)

Editorial: Application of nanotechnology in diagnosis and/or therapy of non-small cell lung cancer
por: Shen, Qinglin, et al.
Publicado: (2023)

Detection of EGFR Mutations in cfDNA and CTCs, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients
por: Liu, Haiyan E., et al.
Publicado: (2020)

What is the appropriate “first lymph node” in the era of segmentectomy for non-small cell lung cancer?
por: Seitlinger, Joseph, et al.
Publicado: (2023)

Immunotherapy in the First-Line Setting in Wild-Type NSCLC
por: Denault, Marie-Hélène, et al.
Publicado: (2021)

Chemo-immunotherapy for metastatic non-squamous NSCLC in a patient with HIV infection: A case report
por: Inno, Alessandro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jpp40620q76h69vkf5mf1nq07u